Table 1.
Distribution of the responses in the 28-day trial
| Year | Treatment | Number included | Parasite clearance on day 3 (ITT) (%) | Observed ACPR | Lost to follow-up and excluded | Reinfection | ITT1 | PP1 |
|---|---|---|---|---|---|---|---|---|
| 2005 | AQ | 64 | 87.5 | 50 | 5 | 5 | 50/64 (55/64) |
50/59 (55/59) |
| AS-AQ | 60 | 100 | 43 | 6 | 10 | 43/60 (53/60) |
43/54 (53/54) |
|
| AS-SP | 61 | 96.8 | 50 | 4 | 4 | 50/61 (54/61) |
50/57 (54/57) |
|
| 2006a | AQ-SP | 67 | 86.6 | 55 | 5 | 7 | 55/67 (62/67) |
55/62 (62/62) |
| AS-MQ | 69 | 95.7 | 60 | 8 | 1 | 60/69 (61/69) |
60/61 (61/61) |
|
| 2006b | AS-AQ | 62 | 98.4 | 52 | 5 | 3 | 52/62 (55/62) |
52/57 (55/57) |
| AM-LM | 61 | 100 | 58 | 1 | 2 | 58/61 (60/61) |
58/60 (60/60) |
|
| 2006c | AS-CD | 83 | 97.6 | 53 | 12 | 7 | 53/83 (60/83) |
53/71 (60/71) |
| AS-SP | 85 | 100 | 73 | 6 | 1 | 73/85 (74/85) |
73/79 (74/79) |
|
| 2007 | AS-AQ | 92 | 99 | 73 | 4 | 8 | 73/92 (81/92) |
73/88 (81/88) |
| DH-PP | 91 | 100 | 84 | 5 | 0 | 84/91 (84/91) |
84/86 (84/86) |
1Values in parentheses denote the observed proportions of ACPR after PCR correction in each treatment group. No recrudescence was observed with the AM-LM combination, and no re-infection was observed with DH-PP. ITT, intention-to-treat; PP, per protocol.